<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2954-3835</journal-id>
<journal-title><![CDATA[Cardiovascular and metabolic science]]></journal-title>
<abbrev-journal-title><![CDATA[Cardiovasc. metab. sci]]></abbrev-journal-title>
<issn>2954-3835</issn>
<publisher>
<publisher-name><![CDATA[Asociación Nacional de Cardiólogos de México A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2954-38352020000200040</article-id>
<article-id pub-id-type="doi">10.35366/94772</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Prevalence and clinical-therapeutic profile of atrial fibrillation in private cardiology offices in northeast Mexico]]></article-title>
<article-title xml:lang="es"><![CDATA[Prevalencia y perfil clínico-terapéutico de la fibrilación auricular en consultorios de cardiología privados del noreste de México]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Solís Olivares]]></surname>
<given-names><![CDATA[Carlos Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez Ríos]]></surname>
<given-names><![CDATA[Sergio Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carrillo Pérez]]></surname>
<given-names><![CDATA[Mario Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Solís Soto]]></surname>
<given-names><![CDATA[Juan Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social (IMSS)  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Tamaulipas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Mexicano del Seguro Social (IMSS)  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad Autónoma de Nuevo León Facultad de Odontología ]]></institution>
<addr-line><![CDATA[Monterrey Nuevo León]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>31</volume>
<numero>2</numero>
<fpage>40</fpage>
<lpage>48</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2954-38352020000200040&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2954-38352020000200040&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2954-38352020000200040&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  The prevalence of atrial fibrillation (AF) in Mexico is unknown.  Objectives:  To document AF prevalence and a clinical-therapeutic profile.  Methods:  Cross-sectional study in three private cardiology offices in Northeast Mexico; in 337 patients from 8,999 clinical records, AF was documented.  Results:  AF prevalence was 3.74%, permanent 56.0%, paroxistic 28.4%, persistent 15.7%; non valvular atrial fibrillation (NVAF) 94.06%. Age 74 ± 12.89 years, women 52.22%, hypertension, 74.18%, smoking, 36.79%, alcoholism 35.01% and type 2 diabetes, 30.56%. The CHA2DS2-VASc &#8805; 2 group vs 0-1, received more anticoagulant (OAC) (31.88 vs 8.33%) and new oral anticoagulant (NOAC) (53.31 vs 13.33%) p &lt; 0.01 for both. In ages 60-75, the CHA2DS2-VASc &#8805; 2 group vs 0-1, received more OAC (34.89 vs 6.25%) p = 0.0004, and NOAC (54.16 vs 0%) p &lt; 0.01. The CHADS group &#8805; 2 vs 0-1, used more OAC (33.6 vs 18.8%) and NOAC (55.17 vs 34.11%) p &lt; 0.01 for both and vitamin K antagonist (VKA) (12.06 vs 3.5%) p = 0.004. The CHA2DS2-VASc group &#8805; 2 vs 0-1, had more women than men (95.03% versus 85.9%), received more diuretics (57.49 vs 13.33), mineralocorticoid receptor antagonist (MRA) (27.52 vs 0%) and angiotensin receptor blockers (ARB) (55.40 vs 16.66%) p &lt; 0.01 for all.  Conclusion:  In our patients, AF is characterized by having a clinical profile of high cardiovascular risk, alcoholism, senility and predominance of women, with a prevalence (3.74%) similar to that of other western countries.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  La prevalencia de fibrilación auricular (FA) en México es desconocida.  Objetivos:  Documentar la prevalencia de FA y su perfil clínico-terapéutico.  Métodos:  Estudio transversal, en tres consultorios privados de cardiología; en 337 de 8,999 expedientes clínicos, la FA fue documentada.  Resultados:  Prevalencia de FA, 3.74%; permanente 56.0%, paroxística 28.4%, persistente 15.7%. FANV 94.06%. Edad, 74 ± 12.89 años, mujeres 52.22%, hipertensión, 74.18%, tabaquismo, 36.79%, alcoholismo 35.01%, diabetes tipo 2, 30.56%. El grupo CHA2DS2-VASc &#8805; 2, comparado al 0-1, recibió más anticoagulación oral ACO (31.88 vs 8.333%) y nuevos anticoagulantes orales (NAO) (53.31 vs 13.33%) p &lt; 0.01 para ambos. En pacientes de 60-75 años, se utilizaron más ACO en el grupo CHA2DS2-VASc &#8805; 2 respecto al 0-1 (34.89 vs 6.25%) p = 0.0004 y NOA (54.16 vs 0%) p &lt; 0.01. El grupo CHADS &#8805; 2 comparado al 0-1, utilizó más ACO (33.6 vs 18.8%) NAO (55.17 vs 34.11%) p &lt; 0.01 para ambos y antagonistas de la vitamina K (AVK) (12.06 vs 3.5%) p = 0.004. El grupo CHA2DS2-VASc &#8805; 2 vs 0-1 tuvo más mujeres que hombres (95.03 vs 85.9%), recibió más diuréticos (57.49 vs 13.33%), antagonistas de los receptores de mineralocorticoides (ARM) (27.52 vs 0%) y bloqueadores de los receptores de angiotensina 2 (BRA 2) (55.40 vs 16.66%) p &lt; 0.01 para todos.  Conclusión:  En nuestros pacientes la FA se caracteriza por tener un perfil de alto riesgo cardiovascular, alcoholismo, senilidad y predominio de mujeres, con una prevalencia (3.74%) similar a la de otros países occidentales.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Atrial fibrillation]]></kwd>
<kwd lng="en"><![CDATA[atrial fibrillation ambulatory prevalence]]></kwd>
<kwd lng="en"><![CDATA[oral anticoagulant]]></kwd>
<kwd lng="en"><![CDATA[new oral anticoagulant]]></kwd>
<kwd lng="en"><![CDATA[vitamin k antagonist]]></kwd>
<kwd lng="en"><![CDATA[mineralocorticoid receptor antagonist]]></kwd>
<kwd lng="en"><![CDATA[angiotensin receptor blockers]]></kwd>
<kwd lng="es"><![CDATA[Fibrilación auricular]]></kwd>
<kwd lng="es"><![CDATA[prevalencia ambulatoria de fibrilación auricular]]></kwd>
<kwd lng="es"><![CDATA[anticoagulante oral]]></kwd>
<kwd lng="es"><![CDATA[nuevos anticoagulantes orales]]></kwd>
<kwd lng="es"><![CDATA[antagonistas de la vitamina K]]></kwd>
<kwd lng="es"><![CDATA[antagonistas de los receptores de mineralocorticoides]]></kwd>
<kwd lng="es"><![CDATA[antagonistas de los receptores de angiotensina II]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is atrial fibrillation a preventable disease?]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2017</year>
<volume>69</volume>
<page-range>1968-82</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zoni-Berisso]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lercari]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Carazza]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Domenicucci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of atrial fibrillation: European perspective]]></article-title>
<source><![CDATA[Clin Epidemiol]]></source>
<year>2014</year>
<volume>6</volume>
<page-range>213-20</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hoshen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reges]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Rabi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Balicer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Leibowitz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2015</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Bawden]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hodson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rutland]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Snachtfold]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Beevers]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation amongst the Indo-Asian general practice population: the West Birmingham Atrial Fibrillation Project]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>1998</year>
<volume>65</volume>
<page-range>187-92</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-Hermosillo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Ocampo-Peña]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Design of an atrial fibrillation and embolic risk registry in México: CARMEN-AF]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2017</year>
<volume>87</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-12</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[January]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Wann]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Calkins]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[Cigarroa]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Cleveland]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 AHA/ACC/HRS focused update if the 2014 guideline for management of patients with atrial fibrillation: a report of American College of Cardiology Foundation/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2019</year>
<volume>16</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>e66-93</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maura]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Billionnet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Drouin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Weill]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Neumann]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pariente]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2019</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodriguez Diez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Iturralde]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pozas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero Cabra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Joint Mexican Position document on the treatment of atrial Fibrillation. Endorsed by: Mexican National Association of Cardiologist (ANCAM), Mexican Electrophysiology and Pacing Society (SOMEEC) and Mexican Society of Cardiology (SMC)]]></article-title>
<source><![CDATA[Cardiovasc Metab Sci]]></source>
<year>2019</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>91-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steinberg]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Gaor]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shrader]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pieper]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF 1, AND ORBIT-AF II, registres]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2017</year>
<volume>194</volume>
<page-range>132-40</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Okeagu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review of race/ethnicity in non vitamin K antagonist oral anticoagulantes clinical trials]]></article-title>
<source><![CDATA[J Thromb Thrombolysis]]></source>
<year>2015</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>222-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Hylek]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apixaban versus warfarin in patients with atrial fibrillation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>365</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>981-92</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amponsah]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Magnani]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation and race - A contemporary review]]></article-title>
<source><![CDATA[Curr Cardiovasc Risk Rep]]></source>
<year>2013</year>
<volume>7</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[CAA]]></given-names>
</name>
<name>
<surname><![CDATA[Lanas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Radaideh]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kharabsheh]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Lambelet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Viaud]]></surname>
<given-names><![CDATA[MAL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[XANTUS-EL: a real-world prospective, observational study of patients treated with rivaroxabán for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America]]></article-title>
<source><![CDATA[Egypt Heart J]]></source>
<year>2018</year>
<volume>70</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>307-13</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lara-Vaca]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero Cabra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Flores]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Iturralde Torres]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Registro Mexicano de Fibrilación Auricular (ReMeFa)]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2014</year>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>48-59</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sardar]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Badri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Prince]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Seltzer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kowey]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Underrepresentation of women, elderly patients and racial minorities in the randomized trial used for cardiovascular guidelines]]></article-title>
<source><![CDATA[JAMA Int Med]]></source>
<year>2014</year>
<volume>174</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1868-70</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simmons]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Falbe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vacek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronary artery disease in women: a review and update]]></article-title>
<source><![CDATA[Rev Cardiovasc Med]]></source>
<year>2011</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e84-93</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[XX]]></given-names>
</name>
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[XX]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sex differences in presentation, quality of life, and treatment in Chinese atrial fibrillation patients: insights from the China Atrial Fibrillation Registry study]]></article-title>
<source><![CDATA[Med Sci Monit]]></source>
<year>2019</year>
<volume>25</volume>
<page-range>8011-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mulvagh]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Merz]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
<name>
<surname><![CDATA[Buring]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Manson]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular disease in women: clinical perspectives]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2016</year>
<volume>118</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1273-93</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Hylek]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Ellinor]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Schnabel]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation in women: treatment]]></article-title>
<source><![CDATA[Nat Rev Cardiol]]></source>
<year>2017</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>113-24</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[EY]]></given-names>
</name>
<name>
<surname><![CDATA[Kong]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gender differences of thromboembolic events in atrial fibrillation]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2016</year>
<volume>117</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1021-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Volterrani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Iellamo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rosano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Guarini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pusineri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bonassi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoagulation in &#8220;real world&#8221; patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2013</year>
<volume>168</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>4729-33</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cools]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wollaert]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vervoort]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Verstraete]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Voet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hermans]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment patterns in anticoagulant therapy in patients with newly diagnoses atrial fibrillation in Belgium: results from the GARFIELD-AF registry]]></article-title>
<source><![CDATA[Act Cardiol]]></source>
<year>2019</year>
<volume>74</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>309-18</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bassand]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Acceta]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cools]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzmaurice]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Two year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2016</year>
<volume>37</volume>
<numero>38</numero>
<issue>38</issue>
<page-range>2882-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
